"10.1371_journal.pone.0061350","plos one","2013-04-19T00:00:00Z","Josquin Nys; Cristian R Smulski; Aubry Tardivel; Laure Willen; Christine Kowalczyk; Olivier Donzé; Bertrand Huard; Henry Hess; Pascal Schneider","Department of Biochemistry, University of Lausanne, Epalinges, Switzerland; Adipogen SA, Epalinges, Switzerland; Department of Patho-Immunology, Medical University Centre, Geneva, Switzerland; Division of Hematology, Geneva University Hospital, Geneva, Switzerland; Merck-Serono, Darmstadt, Germany","Conceived and designed the experiments: JN PS. Performed the experiments: JN CRS LW CK AT PS. Analyzed the data: JN CRS PS. Contributed reagents/materials/analysis tools: OD BH HH. Wrote the paper: HH PS.","The authors have the following interests. This research was financed in part by a research agreement bewteen Merck-Serono and the University of Lausanne. Henry Hess, who is employed by Merck-Serono provided the essential reagent. Olivier Donzé is employed by Adipogen SA. Atacicept, the drug under investigation in this paper, is being developed by Merck-Serono. There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2013","04","Josquin Nys","JN",9,TRUE,2,6,3,2,TRUE,TRUE,FALSE,0,NA,FALSE
